NCT03825601View on ClinicalTrials.gov

PET with [18F]Flumazenil As an Index of Neurodegeneration in MS

NACompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

May 2, 2019

Primary Completion Date

August 26, 2024

Study Completion Date

August 26, 2024

Conditions
Multiple SclerosisRelapsing-Remitting Multiple Sclerosis
Interventions
DIAGNOSTIC_TEST

PET with [11C]Flumazenil

7T MRI sequences : TSE, T2w FLAIR GRE-T2\* and DIR 3T MRI sequences: T1, T2, T1 with gadolinium, magnetization transfer, diffusion weighted, resting state fMRI.

Trial Locations (1)

75651

Centre d'Investigation Clinique de Neuroscience, Groupe Hospitalier Pitié Salpêtrière, ICM, Pitié Salpêtrière, Paris

All Listed Sponsors
lead

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

NCT03825601 - PET with [18F]Flumazenil As an Index of Neurodegeneration in MS | Biotech Hunter | Biotech Hunter